Adverse Effects of JAK Inhibitors
Introduction to Adverse Effects
- JAK inhibitors are associated with several serious side effects, including increased risk of venous thromboembolism, major adverse cardiovascular events, malignancies, serious infections, and various laboratory abnormalities, as reported by the British Journal of Dermatology and the Journal of the American Academy of Dermatology 1, 2
Cardiovascular Risks
- The risk of venous thromboembolism appears to be dose-dependent, with 0.33 events/100 patient-years at lower doses vs 0.70 events/100 patient-years at higher doses, according to the British Journal of Dermatology 1
- The FDA has applied boxed warnings for increased risk of serious heart-related events, as stated in the Journal of the American Academy of Dermatology 2
- Major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular death, are particularly concerning in patients over 65 years old, smokers, and those with a history of cardiovascular disease, as noted in Gastroenterology 3
Infection Risks
- JAK inhibitors can suppress immune function, leading to an increased risk of serious and opportunistic infections, as reported by the Journal of the American Academy of Dermatology 2
- The risk of herpes zoster is significantly increased compared to placebo, and vaccination with recombinant zoster vaccine is recommended before initiating therapy, according to the Journal of the American Academy of Dermatology 2
Hematologic Changes
- Anemia may worsen, especially at treatment initiation, as noted in Annals of Oncology 4
- Lipid elevations require monitoring after treatment initiation, as stated in the Journal of the American Academy of Dermatology 2
Special Populations
- Older adults (>65 years) are at higher risk of cardiovascular complications, as reported in Gastroenterology 3
- Smokers are at increased risk of cardiovascular events, as noted in Gastroenterology 3
- Pregnant women have limited safety data, and JAK inhibitors should be avoided in women contemplating pregnancy, according to Gastroenterology 3
Discontinuation and Monitoring
- Sudden withdrawal of JAK inhibitors can provoke a shock-like syndrome, and tapering is recommended rather than abrupt discontinuation, as stated in Annals of Oncology 4
- Regular monitoring, including complete blood count, liver function tests, lipid profile, and tuberculosis screening, is necessary during treatment, as recommended by the Journal of the American Academy of Dermatology 2
The following tests are recommended before initiating JAK inhibitors:
Test Frequency Complete blood count with differential 4-12 weeks after initiation and every 3-6 months Liver function tests 4 weeks after initiation Renal function assessment Before initiation Lipid profile Before initiation and after treatment initiation Tuberculosis screening Before initiation Hepatitis B and C testing Before initiation HIV testing Before initiation in high-risk populations Venous thromboembolism risk assessment Before initiation Vaccination status assessment Before initiation
Treatment Selection and Dosing
- JAK inhibitors should be selected based on their specific JAK-targeting profile (JAK1, JAK2, or JAK3) to match the underlying disease pathophysiology, with careful consideration of safety monitoring requirements and patient-specific risk factors 5, 1
- Consider JAK inhibitors in patients who have failed conventional and/or biological therapies, according to the American College of Rheumatology 5
- Add JAK inhibitors to continued conventional synthetic DMARDs if tolerated, as recommended by the European League Against Rheumatism 5
- Use the recommended dose for the specific disease, and consider dose adjustments in patients >70 years, impaired renal or hepatic function, drug interaction risk, and other comorbidities, as recommended by the European League Against Rheumatism 5
- Consider dose reduction in patients achieving sustained remission, according to the American College of Rheumatology 5
Contraindications and Precautions
- Severe active infections, current malignancies, severe hepatic disease, severe renal disease, pregnancy and lactation, and recurrent venous thromboembolism are contraindications for JAK inhibitors, as stated by the American College of Rheumatology 5, 1
- Serious infections, herpes zoster, venous thromboembolism, cardiovascular events, malignancy, and laboratory abnormalities are potential risks associated with JAK inhibitors, as reported by the American Academy of Dermatology and the British Society for Rheumatology 2, 1
- Use JAK inhibitors with caution in patients with cardiovascular risk factors, and consider lower starting doses, as suggested by the American Gastroenterological Association and the British Society for Rheumatology 3, 1
- Carefully assess the risk-benefit ratio and consider alternative therapies in patients with multiple risk factors, as recommended by the American Gastroenterological Association 3
- Avoid JAK inhibitors in women contemplating pregnancy, due to limited safety data, as stated by the American Gastroenterological Association 3
- Complete all required vaccinations before initiating therapy, particularly recombinant zoster vaccine for patients >18 years, as recommended by the British Society for Rheumatology 1
- Monitor for signs of infection and temporarily discontinue during serious infections, according to the British Society for Rheumatology 1